Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Sutent | Sunitinib | Gastrointestinal stromal tumour (GIST) | List with clinical criteria and/or conditions | Complete | ||
Sutent | Sunitinib malate | Cancer, Metastatic renal cell carcinoma | Do not list | Complete | ||
Sylvant | Siltuximab | Multicentric Castleman's disease (MCD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Symdeko | tezacaftor/ivacaftor | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
Symtuza | Darunavir/cobicistat/emtricitabine/tenofovir alafenamide | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
Synjardy | Empagliflozin and metformin | Diabetes mellitus (Type 2) | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar | Dabrafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete |